Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines

被引:0
作者
Stearns, ME [1 ]
Wang, M
Hu, YJ
Garcia, FU
Rhim, J
机构
[1] Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Rockville, MD 20817 USA
[2] Med Coll Penn & Hahnemann Univ, Dept Pathol, Philadelphia, PA 19102 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Insulin-like growth factor (IGF) I has been shown previously to up-regulate matrix metalloproteinase-2 (MMP-2) production, whereas the interleukin (IL) 10/ IL-10 receptor axis has been found to down-regulate MMP-2 synthesis in tumor cells. In this paper, we showed that IL-10 activation of the IL-10 receptor blocked MMP-2 and membrane type 1 (MT1) -MMP transcription and protein synthesis in nonimmortalized primary human prostate cell strains (i.e., HPCA-10a and HPCA-10c) derived from high-grade cancer. Northern blots, Western blots, and ELISAs showed that IL-10 suppressed IGF-I induction of MMP-2 and MT1-MMP mRNA synthesis in these cell strains (P < 0.001). Inhibition studies with IL-10 and IGF-I receptor antibodies plus transfections experiments with IL-10 sense, and IGF-I receptor antisense constructs confirmed these results. Finally, transient transfection experiments and chloramphenicol acetyltransferase assays with different regions of the 5' promoter region of the MMP-2 gene (-1659 to -555 bp) additionally showed that IGF-I stimulated p53-dependent plasmid catecholamine acetyltransferase activity and that IL-10 blocked IGF-I-induced plasmid catecholamine acetyltransferase activity. Electrophoretic mobility shift assays revealed that IL-10 induced protein(s) binding to a putative "silencer element" (-1309 to -555 fragment) downstream of the p53 binding site (-1649 to -1640). The data show that IL-10 blocks IGF-I activation of MMP-2 and MT1-MMP mRNA expression and protein synthesis in primary prostate cell strains.
引用
收藏
页码:1191 / 1199
页数:9
相关论文
共 28 条
[1]  
AZNAVOORIAN S, 1993, CANCER, V71, P13678
[2]   Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter [J].
Bian, JH ;
Sun, Y .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (11) :6330-6338
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo [J].
Burfeind, P ;
Chernicky, CL ;
Rininsland, F ;
Ilan, J ;
Ilan, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :7263-7268
[5]   TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP, AKA EPA) - STRUCTURE, CONTROL OF EXPRESSION AND BIOLOGICAL FUNCTIONS [J].
DENHARDT, DT ;
FENG, B ;
EDWARDS, DR ;
COCUZZI, ET ;
MALYANKAR, UM .
PHARMACOLOGY & THERAPEUTICS, 1993, 59 (03) :329-341
[6]  
Deryugina EI, 1998, CANCER RES, V58, P3743
[7]  
FINBLOOM DS, 1995, J IMMUNOL, V155, P1079
[8]  
Greene GF, 1997, AM J PATHOL, V150, P1571
[9]  
Kimura G, 1996, Int J Urol, V3, P39
[10]   The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity [J].
Ko, YC ;
Langley, KE ;
Mendiaz, EA ;
Parker, VP ;
Taylor, SM ;
DeClerck, YA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (01) :100-105